Pacific Edge Ltd
Price Chart
OHLC · volume · moving averages
Market Statistics
Today's trading range
Valuation
Fundamental multiples
Trading Activity
Volume & order book
Performance
Returns across timeframes
Technical Indicators
Momentum & moving averages
— From the desk
Latest News
Pacific Edge’s Cxbladder Triage biomarker test recognised as standard of care in AUA guideline update
New Zealand-based cancer diagnostics company Pacific Edge (ASX: PEB) has had its Cxbladder Triage test included as a standard of care by the American Urological Association (AUA). In a major amendment to the 2020 AUA microhematuria guideline, the AUA panel has incorporated language for the use of urine-based biomarkers for intermediate-risk patients. Most notably, it […]
Medtech firms assessing impact of proposed FDA regulation changes
Local medtech companies are rushing to assess proposed new US Food and Drug Administration (FDA) rule changes that seek to have laboratory developed tests (LDTs) regulated as medical devices under the US Federal Food, Drug, and Cosmetic Act. The proposed changes are being aggressively opposed by numerous associations including the Coalition for 21st Century Medicine […]
Market wrap: good news on jobs turns to bad news for shares
Once again, the Australian share market turned good economic news into a bad share performance as the ASX 200 index slumped to a three-month low of just 7042.3 points. Hot US jobs figures from ADP Research found that employers added 497,000 jobs in June – nearly double what was expected – driving most traders to […]
Pacific Edge battles out proposed end of US Medicare coverage for Cxbladder tests
New Zealand company Pacific Edge (ASX: PEB) has updated its billing policies in the US for its range of Cxbladder non-invasive genomic urine tests for the detection and management of bladder cancer. From 17 July, the company will provide for enhanced patient responsibility in cases where a patient’s health insurer declines to pay for a […]